SNDX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Syndax discontinues development of axatilimab for idiopathic pulmonary fibrosisOct 14, 2026
- Syndax announces topline results from the Phase 2 MAXPIRe trial evaluating axatilimab in idiopathic pulmonary fibrosisOct 12, 2026
- Syndax published SAVE study data for Revuforj combination therapy in relapsed or refractory AMLJun 11, 2026
- Syndax and World Orphan Drug Alliance launched multi-regional access program for Revuforj®Jan 7, 2026
- Syndax announces FDA approval of Revuforj® (revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemiaOct 27, 2025